JP2021511360A5 - - Google Patents
Info
- Publication number
- JP2021511360A5 JP2021511360A5 JP2020540751A JP2020540751A JP2021511360A5 JP 2021511360 A5 JP2021511360 A5 JP 2021511360A5 JP 2020540751 A JP2020540751 A JP 2020540751A JP 2020540751 A JP2020540751 A JP 2020540751A JP 2021511360 A5 JP2021511360 A5 JP 2021511360A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- alkylene
- cycloalkyl
- heterocycloalkyl
- Prior art date
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023083168A JP7690517B2 (ja) | 2018-01-26 | 2023-05-19 | キナーゼ依存的障害を処置するための化合物 |
| JP2025089864A JP2025128208A (ja) | 2018-01-26 | 2025-05-29 | キナーゼ依存的障害を処置するための化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622702P | 2018-01-26 | 2018-01-26 | |
| US62/622,702 | 2018-01-26 | ||
| US201862758321P | 2018-11-09 | 2018-11-09 | |
| US62/758,321 | 2018-11-09 | ||
| PCT/US2019/015297 WO2019148044A1 (en) | 2018-01-26 | 2019-01-25 | Compounds for the treatment of kinase-dependent disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083168A Division JP7690517B2 (ja) | 2018-01-26 | 2023-05-19 | キナーゼ依存的障害を処置するための化合物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021511360A JP2021511360A (ja) | 2021-05-06 |
| JP2021511360A5 true JP2021511360A5 (https=) | 2022-02-01 |
| JPWO2019148044A5 JPWO2019148044A5 (https=) | 2022-02-01 |
| JP7321165B2 JP7321165B2 (ja) | 2023-08-04 |
Family
ID=65409544
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540751A Active JP7321165B2 (ja) | 2018-01-26 | 2019-01-25 | キナーゼ依存的障害を処置するための化合物 |
| JP2023083168A Active JP7690517B2 (ja) | 2018-01-26 | 2023-05-19 | キナーゼ依存的障害を処置するための化合物 |
| JP2025089864A Pending JP2025128208A (ja) | 2018-01-26 | 2025-05-29 | キナーゼ依存的障害を処置するための化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083168A Active JP7690517B2 (ja) | 2018-01-26 | 2023-05-19 | キナーゼ依存的障害を処置するための化合物 |
| JP2025089864A Pending JP2025128208A (ja) | 2018-01-26 | 2025-05-29 | キナーゼ依存的障害を処置するための化合物 |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US11542259B2 (https=) |
| EP (2) | EP4647127A3 (https=) |
| JP (3) | JP7321165B2 (https=) |
| KR (2) | KR102721118B1 (https=) |
| CN (5) | CN117624045A (https=) |
| AU (2) | AU2019212801B2 (https=) |
| BR (1) | BR112020015201A2 (https=) |
| CA (1) | CA3088200A1 (https=) |
| CL (2) | CL2020001931A1 (https=) |
| CO (1) | CO2020010465A2 (https=) |
| CR (2) | CR20230287A (https=) |
| DK (1) | DK3743070T3 (https=) |
| ES (1) | ES3048989T3 (https=) |
| FI (1) | FI3743070T3 (https=) |
| GE (2) | GEAP202415420A (https=) |
| HR (1) | HRP20251184T1 (https=) |
| HU (1) | HUE073371T2 (https=) |
| IL (3) | IL321138A (https=) |
| LT (1) | LT3743070T (https=) |
| MA (1) | MA51673B1 (https=) |
| MX (2) | MX2020007765A (https=) |
| MY (1) | MY210421A (https=) |
| PE (2) | PE20242219A1 (https=) |
| PH (1) | PH12020551208A1 (https=) |
| PL (1) | PL3743070T3 (https=) |
| PT (1) | PT3743070T (https=) |
| RS (1) | RS67317B1 (https=) |
| SA (1) | SA520412500B1 (https=) |
| SG (1) | SG11202006921PA (https=) |
| SI (1) | SI3743070T1 (https=) |
| SM (1) | SMT202500395T1 (https=) |
| UA (1) | UA128476C2 (https=) |
| WO (1) | WO2019148044A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA51679A (fr) | 2018-01-26 | 2020-12-02 | Exelixis Inc | Composés destinés au traitement de troubles dépendant de la kinase |
| UA128476C2 (uk) * | 2018-01-26 | 2024-07-24 | Екселіксіс, Інк. | Сполуки для лікування кіназозалежних розладів |
| CA3118752A1 (en) | 2018-11-09 | 2020-05-14 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| PL3894012T4 (pl) * | 2018-12-13 | 2026-01-05 | Exelixis, Inc. | Postacie krystaliczne i postacie soli inhibitora kinazy |
| AU2020210863B2 (en) * | 2019-01-25 | 2025-10-23 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| CN109761899B (zh) * | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
| HUE070525T2 (hu) * | 2019-04-16 | 2025-06-28 | Vivace Therapeutics Inc | Biciklusos vegyületek |
| CA3139148A1 (en) * | 2019-06-03 | 2020-12-10 | Exelixis, Inc. | Crystalline salt forms of a kinase inhibitor |
| AR119069A1 (es) | 2019-06-04 | 2021-11-24 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de quinasas |
| CN110845406B (zh) * | 2019-12-04 | 2021-07-20 | 广州安岩仁医药科技有限公司 | 喹啉类化合物的制备方法 |
| EP4103188A4 (en) * | 2020-02-10 | 2024-04-10 | StemSynergy Therapeutics, Inc. | Myc inhibitors and uses thereof |
| TWI887405B (zh) * | 2020-04-30 | 2025-06-21 | 美商艾克塞里克斯公司 | 製備激酶抑制劑之方法 |
| EP4188376A1 (en) * | 2020-07-31 | 2023-06-07 | Exelixis, Inc. | Combinations for the treatment of cancer |
| CR20230223A (es) | 2020-11-05 | 2023-07-07 | Exelixis Inc | Composiciones farmacéuticas de un inhibidor de cinasa |
| TW202241862A (zh) * | 2021-02-01 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 二甲醯胺類化合物、其製備方法及其在醫藥上的應用 |
| KR20230147139A (ko) * | 2021-02-17 | 2023-10-20 | 스프링웍스 테라퓨틱스, 인크. | Mek 저해제인 n-((r)-2,3-다이하이드록시프로폭시)-3,4-다이플루오로-2-(2-플루오로-4-아이오도페닐아미노)-벤즈아마이드의 결정질 고체 및 이의 용도 |
| CN113582924A (zh) * | 2021-09-09 | 2021-11-02 | 四川国康药业有限公司 | 一种多靶点酪氨酸激酶抑制剂及其制备方法和用途 |
| TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
| TW202340148A (zh) | 2021-12-22 | 2023-10-16 | 美商艾克塞里克斯公司 | 激酶抑制劑之結晶形式及鹽形式 |
| CN114573553B (zh) * | 2022-01-27 | 2023-11-10 | 广州六顺生物科技有限公司 | 杂芳环类衍生物及其制备方法和应用 |
| CN116655626B (zh) * | 2023-05-24 | 2025-03-11 | 遵义医科大学 | 一种含咪唑并[l，2-a]吡啶骨架的环丙二酰胺化合物及其制备方法和用途 |
| CN116751161A (zh) * | 2023-06-28 | 2023-09-15 | 中国人民解放军军事科学院军事医学研究院 | 喹啉类化合物及其制备方法、药物组合物及医药用途 |
| WO2025253311A1 (en) | 2024-06-04 | 2025-12-11 | Hetero Labs Limited | 1,2-dicarboxamide compounds as kinase inhibitors |
| WO2026074526A1 (en) | 2024-10-04 | 2026-04-09 | Hetero Labs Limited | 1,2-dicarboxamide compounds as kinase inhibitors |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| MX9707453A (es) | 1995-03-30 | 1997-12-31 | Pfizer | Derivados de quinazolina. |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| DE60137273D1 (de) * | 2000-10-20 | 2009-02-12 | Eisai R&D Man Co Ltd | Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten |
| PT2213661E (pt) * | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| WO2006113546A2 (en) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN101316590B (zh) * | 2005-11-07 | 2011-08-03 | 卫材R&D管理有限公司 | 血管生成抑制剂和c-kit激酶抑制剂的组合使用 |
| EP2340244A4 (en) * | 2008-10-14 | 2012-07-25 | Ning Xi | COMPOUNDS AND APPLICATION PROCEDURES |
| SG173014A1 (en) | 2009-01-16 | 2011-08-29 | Exelixis Inc | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
| EP2214019A1 (en) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Tumor markers and methods of use thereof |
| EP2213686A1 (en) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Tumor markers and methods of use thereof |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| WO2011051271A2 (en) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Prostate tumor markers and methods of use thereof |
| WO2011051277A1 (en) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Breast tumor markers and methods of use thereof |
| EP2493916B1 (en) | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Lung tumor markers and methods of use thereof |
| EP2494361B2 (en) | 2009-10-26 | 2019-01-09 | Externautics S.p.A. | Ovary tumor markers and methods of use thereof |
| EP2494351B1 (en) | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Colon and rectal tumor markers and methods of use thereof |
| US20120070368A1 (en) * | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| EP2383578A1 (en) | 2010-04-30 | 2011-11-02 | Externautics S.p.A. | Tumor marker and methods of use thereof |
| WO2012006960A1 (en) | 2010-07-14 | 2012-01-19 | Zhejiang Beta Pharma Inc. | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
| EP2593090B1 (en) | 2010-07-16 | 2021-10-13 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| CA2812750C (en) | 2010-09-27 | 2020-10-06 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases |
| CN102093421B (zh) | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| JP2014505109A (ja) | 2011-02-10 | 2014-02-27 | エクセリクシス， インク． | キノリン化合物およびそのような化合物を含有する医薬組成物の調製方法 |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| KR20140025496A (ko) | 2011-05-02 | 2014-03-04 | 엑셀리시스, 인코포레이티드 | 암 및 뼈 암 통증의 치료방법 |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| GEP201606523B (en) | 2011-09-22 | 2016-08-10 | Exelixis Inc | Method for treating osteoporosis |
| DK2768796T3 (da) | 2011-10-20 | 2020-02-24 | Exelixis Inc | Fremgangsmåde til fremstilling af quinolin-derivater |
| JP2014532766A (ja) | 2011-11-08 | 2014-12-08 | エクセリクシス， インク． | 癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤 |
| EP2775921A1 (en) | 2011-11-08 | 2014-09-17 | Exelixis, Inc. | Method of quantifying cancer treatment |
| JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス， インク． | 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤 |
| CN114129566A (zh) | 2012-09-07 | 2022-03-04 | 埃克塞里艾克西斯公司 | 用于治疗肺腺癌的met、vegfr和ret的抑制剂 |
| CA2886433C (en) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| AU2014232714B2 (en) | 2013-03-15 | 2018-07-19 | Exelixis, Inc. | Metabolites of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
| BR112015025408A8 (pt) | 2013-04-04 | 2018-07-10 | Exelixis Inc | combinações de drogas para tratar câncer |
| EP2981263B1 (en) | 2013-04-04 | 2022-06-29 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US10359428B2 (en) | 2013-06-14 | 2019-07-23 | Externautics S.P.A. | Tumor marker, monoclonal antibodies and methods of use thereof |
| KR20160093012A (ko) | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
| KR102354963B1 (ko) | 2014-02-14 | 2022-01-21 | 엑셀리시스, 인코포레이티드 | N-｛4-[(6,7-다이메톡시퀴놀린-4-일)옥시]페닐｝-n'-(4-플루오로페닐) 사이클로프로판-1,1-다이카복스아마이드의 결정질 고체 형태, 제조 방법 및 사용 방법 |
| EA201691850A1 (ru) | 2014-03-17 | 2016-12-30 | Экселиксис, Инк. | Дозирование составов, содержащих кабозантиниб |
| IL248408B (en) | 2014-04-25 | 2022-06-01 | Exelixis Inc | A method for treating adenocarcinoma of the lungs |
| ES2929888T3 (es) | 2014-07-31 | 2022-12-02 | Exelixis Inc | Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos |
| BR112017002318A2 (pt) | 2014-08-05 | 2018-07-17 | Exelixis, Inc. | combinações de fármacos para tratar mieloma múltiplo. |
| CN104817497B (zh) | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| CN106279147A (zh) | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| US20180009758A1 (en) | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| US20160376239A1 (en) | 2015-06-29 | 2016-12-29 | Ontogenesis, Llc | N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use |
| US20170342033A1 (en) * | 2015-06-29 | 2017-11-30 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| RU2748549C2 (ru) | 2016-04-15 | 2021-05-26 | Экселиксис, Инк. | Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата |
| US20210030737A1 (en) | 2016-04-19 | 2021-02-04 | Exelixis, Inc. | Triple Negative Breast Cancer Treatment Method |
| CN105797123A (zh) | 2016-05-18 | 2016-07-27 | 王超 | 一种治疗不孕不育的中药组合物 |
| CN106400155A (zh) | 2016-08-31 | 2017-02-15 | 飞佛特种纺织品（宁波）有限公司 | 一种防老化阳光面料 |
| CN107235896B (zh) * | 2016-09-13 | 2019-11-05 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| CA3038500A1 (en) | 2016-09-27 | 2018-04-05 | Andrea B. Apolo | Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| KR20230169458A (ko) | 2017-01-20 | 2023-12-15 | 엑셀리시스, 인코포레이티드 | 암을 치료하기 위한 카보잔티닙 및 아테졸리주맙의 조합 |
| US10800741B2 (en) * | 2017-02-07 | 2020-10-13 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Quinoline compound, preparation method and medical use therefor |
| AU2018272088C1 (en) | 2017-05-26 | 2022-09-22 | Exelixis, Inc. | Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-N'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| EP3634413A1 (en) | 2017-06-09 | 2020-04-15 | Exelixis, Inc. | Liquid dosage forms to treat cancer |
| SG11202005719UA (en) | 2017-12-20 | 2020-07-29 | Angex Pharmaceutical Inc | Carbamate and urea compounds as multikinase inhibitors |
| US20190262330A1 (en) | 2017-12-21 | 2019-08-29 | Exelixis, Inc. | Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
| MA51679A (fr) * | 2018-01-26 | 2020-12-02 | Exelixis Inc | Composés destinés au traitement de troubles dépendant de la kinase |
| UA128476C2 (uk) * | 2018-01-26 | 2024-07-24 | Екселіксіс, Інк. | Сполуки для лікування кіназозалежних розладів |
| UA128348C2 (uk) * | 2018-01-26 | 2024-06-19 | Екселіксіс, Інк. | Сполуки для лікування кіназозалежних розладів |
| PL3894012T4 (pl) * | 2018-12-13 | 2026-01-05 | Exelixis, Inc. | Postacie krystaliczne i postacie soli inhibitora kinazy |
| AU2020210863B2 (en) * | 2019-01-25 | 2025-10-23 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| CA3139148A1 (en) * | 2019-06-03 | 2020-12-10 | Exelixis, Inc. | Crystalline salt forms of a kinase inhibitor |
| AR119069A1 (es) * | 2019-06-04 | 2021-11-24 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de quinasas |
| TWI887405B (zh) * | 2020-04-30 | 2025-06-21 | 美商艾克塞里克斯公司 | 製備激酶抑制劑之方法 |
| EP4188376A1 (en) * | 2020-07-31 | 2023-06-07 | Exelixis, Inc. | Combinations for the treatment of cancer |
| CR20230223A (es) * | 2020-11-05 | 2023-07-07 | Exelixis Inc | Composiciones farmacéuticas de un inhibidor de cinasa |
| TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
| TW202340148A (zh) * | 2021-12-22 | 2023-10-16 | 美商艾克塞里克斯公司 | 激酶抑制劑之結晶形式及鹽形式 |
-
2019
- 2019-01-25 UA UAA202005455A patent/UA128476C2/uk unknown
- 2019-01-25 CN CN202311144729.1A patent/CN117624045A/zh active Pending
- 2019-01-25 LT LTEPPCT/US2019/015297T patent/LT3743070T/lt unknown
- 2019-01-25 MY MYPI2020003771A patent/MY210421A/en unknown
- 2019-01-25 SI SI201930984T patent/SI3743070T1/sl unknown
- 2019-01-25 MA MA51673A patent/MA51673B1/fr unknown
- 2019-01-25 BR BR112020015201-3A patent/BR112020015201A2/pt active Search and Examination
- 2019-01-25 AU AU2019212801A patent/AU2019212801B2/en active Active
- 2019-01-25 PL PL19704970.3T patent/PL3743070T3/pl unknown
- 2019-01-25 CN CN202311131715.6A patent/CN117603138A/zh active Pending
- 2019-01-25 IL IL321138A patent/IL321138A/en unknown
- 2019-01-25 CR CR20230287A patent/CR20230287A/es unknown
- 2019-01-25 RS RS20251022A patent/RS67317B1/sr unknown
- 2019-01-25 PE PE2024001872A patent/PE20242219A1/es unknown
- 2019-01-25 WO PCT/US2019/015297 patent/WO2019148044A1/en not_active Ceased
- 2019-01-25 FI FIEP19704970.3T patent/FI3743070T3/fi active
- 2019-01-25 KR KR1020207024581A patent/KR102721118B1/ko active Active
- 2019-01-25 IL IL300824A patent/IL300824A/en unknown
- 2019-01-25 GE GEAP202415420A patent/GEAP202415420A/en unknown
- 2019-01-25 CN CN201980015066.9A patent/CN111757735B/zh active Active
- 2019-01-25 PE PE2020001121A patent/PE20211203A1/es unknown
- 2019-01-25 EP EP25191104.6A patent/EP4647127A3/en active Pending
- 2019-01-25 KR KR1020247034878A patent/KR20240155380A/ko not_active Ceased
- 2019-01-25 JP JP2020540751A patent/JP7321165B2/ja active Active
- 2019-01-25 GE GEAP201915420A patent/GEP20257770B/en unknown
- 2019-01-25 CN CN202311157242.7A patent/CN117402114A/zh active Pending
- 2019-01-25 CN CN202311123887.9A patent/CN117820226A/zh active Pending
- 2019-01-25 HU HUE19704970A patent/HUE073371T2/hu unknown
- 2019-01-25 SM SM20250395T patent/SMT202500395T1/it unknown
- 2019-01-25 CA CA3088200A patent/CA3088200A1/en active Pending
- 2019-01-25 MX MX2020007765A patent/MX2020007765A/es unknown
- 2019-01-25 HR HRP20251184TT patent/HRP20251184T1/hr unknown
- 2019-01-25 ES ES19704970T patent/ES3048989T3/es active Active
- 2019-01-25 EP EP19704970.3A patent/EP3743070B1/en active Active
- 2019-01-25 DK DK19704970.3T patent/DK3743070T3/da active
- 2019-01-25 PT PT197049703T patent/PT3743070T/pt unknown
- 2019-01-25 SG SG11202006921PA patent/SG11202006921PA/en unknown
- 2019-01-25 CR CR20200358A patent/CR20200358A/es unknown
- 2019-01-25 US US16/964,330 patent/US11542259B2/en active Active
-
2020
- 2020-07-13 IL IL276032A patent/IL276032A/en unknown
- 2020-07-22 MX MX2022016051A patent/MX2022016051A/es unknown
- 2020-07-23 SA SA520412500A patent/SA520412500B1/ar unknown
- 2020-07-23 CL CL2020001931A patent/CL2020001931A1/es unknown
- 2020-08-07 PH PH12020551208A patent/PH12020551208A1/en unknown
- 2020-08-25 CO CONC2020/0010465A patent/CO2020010465A2/es unknown
-
2022
- 2022-11-17 US US17/989,393 patent/US20240043414A1/en not_active Abandoned
-
2023
- 2023-05-19 JP JP2023083168A patent/JP7690517B2/ja active Active
-
2024
- 2024-08-01 AU AU2024205373A patent/AU2024205373A1/en active Pending
- 2024-08-09 CL CL2024002398A patent/CL2024002398A1/es unknown
-
2025
- 2025-05-29 JP JP2025089864A patent/JP2025128208A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021511360A5 (https=) | ||
| JPWO2019148044A5 (https=) | ||
| JP5576485B2 (ja) | 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール | |
| JP6506836B2 (ja) | Ｂ型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン | |
| JP2021534124A5 (https=) | ||
| JP2019534291A5 (https=) | ||
| JP2009545611A5 (https=) | ||
| JP2021511359A5 (https=) | ||
| JP2008509187A5 (https=) | ||
| JP2008504292A5 (https=) | ||
| JP2009507909A5 (https=) | ||
| JP2010031025A5 (https=) | ||
| JP2007534702A5 (https=) | ||
| JP2014500265A5 (https=) | ||
| JP2021511357A5 (https=) | ||
| JP2022119852A5 (https=) | ||
| CA2547347A1 (en) | Diazaindole-dicarbonyl-piperazinyl antiviral agents | |
| JP2011510072A5 (https=) | ||
| JP2012506908A5 (https=) | ||
| WO2009094845A1 (en) | 5-(3-heteroaromatic ring substituted phenyl) tetrazole compounds and their uses for anti-hiv/aids | |
| JP2018065817A (ja) | 抗ウイルス活性を有するメタンチオン化合物 | |
| JP2015515465A5 (https=) | ||
| JP2007522188A (ja) | 置換ベンゾイミダゾール及びアポトーシスを誘導するためのこれらの使用 | |
| JPWO2019148036A5 (https=) | ||
| JP2012505892A5 (https=) |